1 October 2024 - The October 2024 issue of the New Zealand Pharmaceutical Schedule is now available and in effect.

There are a few new/revised listings of note this month:

• Pembrolizumab (Keytruda) - breast cancer
• Pembrolizumab (Keytruda) - bladder cancer
• Pembrolizumab (Keytruda) - colorectal cancer
• Pembrolizumab (Keytruda) - head and neck cancer
• Pembrolizumab (Keytruda) - Hodgkin's disease

Read New Zealand Pharmaceutical Schedule update